I have owned this stock for over 3 years. I was just filing away my 2009 annual report and came across 2008 and 2007 annual reports. When you open the annual report the 1st pg has all their drugs under development. Well guess what? The graph has hardly changed in over 3 years. 3 years ago they had 4 drugs in phase#2 and this year they have 3. CRF1 antagonist(876008) is no longer on the chart due to disapointing results. It just amazes me that they can have 3 drugs get stuck in phase#2 for so long? Not sure if I should be excited that we should get more info on Elagolix at the end of this month or not. All I know is I am not holding my breath. This bioscience busines is definitly not for the day trader... My question for any one out there that follow other companies. would this be abnormally long to have 3 drugs in phase #2 or is that normal?